Daniil Stroyakovsky - Concepedia

Author

Daniil Stroyakovsky

Also Known As

D. L. Stroyakovsky, D. Stroyakovsky, D.L. Stroyakovsky, D. L. Stroyakovsky, Daniil L. Stroyakovsky, Daniil Stroyakovsky

Publications

198

Citations

H-Index

Concepts

All Affiliations

Daniil Stroyakovsky is an author at Moscow City Oncology Hospital №62 specializing in medicine, oncology, and pharmacology.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	168
2	Pharmacology	4	4	168
3	Cancer Therapeutics	3	3	155
4	Health Sciences	1	1	13
5	Immunology	1	1	69

Daniil Stroyakovsky

Publications

168

Citations

H-Index

Page 1

	Year	Citations
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer Mark A. Socinski, G. Manikhas, Daniil Stroyakovsky, Journal of Thoracic Oncology First-line TherapyOncologyPharmacologyBronchial NeoplasmCancer Treatment	2010	75
COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF<sup>V600E/K </sup>mutation-positive cutaneous melanoma Georgina V. Long, Daniil Stroyakovsky, Helen Gogas, Journal of Clinical Oncology First-line TherapyImmunologyPharmacotherapyImmunotherapeuticsDermatology	2014	69
Pharmacokinetics and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin in patients. Sergey Orlov, Olga Burdaeva, Marina P. Nechaeva, Journal of Clinical Oncology PharmacotherapyBevacizumab Biosimilar CandidatePre-clinical PharmacologySingle Bcd-021Clinical Trials	2014	13
Pharmacokinetics and safety of BCD-022, trastuzumab biosimilar candidate, compared to Herceptin in patients. E. Ignatova, Olga Burdaeva, Marina P. Nechaeva, Journal of Clinical Oncology Single Bcd-022Therapeutic Drug MonitoringTranslational MedicineOncologyMedicine	2014	11

Page 1